Valproic acid increases SMN levels in spinal muscular atrophy patient cells

Charlotte J. Sumner(National Institute of Neurological Disorders and Stroke), Thanh N. Huynh(National Institute of Neurological Disorders and Stroke), Jennifer A. Markowitz(National Institute of Neurological Disorders and Stroke), J. Stephen Perhac(National Institute of Neurological Disorders and Stroke), Brenna J. Hill(National Institute of Allergy and Infectious Diseases), Daniel D. Coovert(University of Minnesota), Kristie R. Schussler(The Ohio State University), Xiaocun Chen(Vertex Pharmaceuticals (United States)), Jill Jarecki(Vertex Pharmaceuticals (United States)), Arthur H.M. Burghes(University of Minnesota), J. Paul Taylor(National Institute of Neurological Disorders and Stroke), Kenneth H. Fischbeck(National Institute of Neurological Disorders and Stroke)
Annals of Neurology
October 22, 2003
Cited by 288

Abstract

Spinal muscular atrophy (SMA) is an inherited motor neuron disease caused by mutation of the telomeric copy of the survival motor neuron gene (SMN1). Although a centromeric copy of the survival motor neuron gene (SMN2) is retained in all patients with SMA, it differs from SMN1 at a critical nucleotide such that the majority of SMN2 transcripts lack exon 7 and encode an unstable, truncated protein. Here, we show that valproic acid increases levels of exon 7-containing SMN transcript and SMN protein in type I SMA patient-derived fibroblast cell lines. Valproic acid may increase SMN levels both by activating the SMN promoter and by preventing exon 7 skipping in SMN transcripts. Valproic acid and related compounds warrant further investigation as potential treatment for SMA.


Related Papers

No related papers found

Powered by citation graph analysis